Inflammatory Bowel Disease | McMaster Farncombe Institute

Introduction

John Marshall and Walter Reinisch are involved in several phase 2 and phase 3 randomized trials that evaluate the latest therapies in both Crohn’s disease and ulcerative colitis (UC). Walter Reinisch is conducting studies with Wali Khan to assess how fecal calprotectin and be used to optimize the management of IBD patients. Walter Reinsich is also evaluating novel approaches to managing IBD patients in remote places as well as developing tools that will optimize the quality of care for IBD patients. Paul Moayyedi, Michael Surette and Christine Lee have led the world’s first randomized trial evaluating fecal microbiota therapy in UC. Work is currently ongoing to evaluate how this approach can be optimized to treat UC patients.

Relevant Papers

Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. -
Moayyedi Paul, Surette Michael G, Kim Peter T et al.
Gastroenterology. Link: 25857665

Lack of utility of symptoms and signs at first presentation as predictors of inflammatory bowel disease in secondary care. -
Ford Alexander C, Moayyedi Paul, Bercik Premysl et al.
Am J Gastroenterol. Link: 25916225